Dr. Robert W. Davis, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 202
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
OR license MD203828 -
Hospitalist Physician
NY license 289595
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Good Samaritan Regional Medical Center Corvallis, OR
- Samaritan Albany General Hospital Albany, OR
- Samaritan PAcific Community Hospital Newport, OR
- Samaritan Lebanon Community Hospital Lebanon, OR
Medical groups
- Good Samaritan Hospital Corvallis (380 clinicians)
- Mid-Valley Healthcare Inc (147 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 202
- Services billed
- 923
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 153 | 52 |
| Established patient office or other outpatient visit, 30-39 minutes | 140 | 97 |
| Established patient office or other outpatient visit, 20-29 minutes | 32 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 25 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 18 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 16 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Corvallis, OR | 124 |
| Tamoxifen Citrate Other prescribers in Corvallis, OR | 115 |
| Eliquis (apixaban) Other prescribers in Corvallis, OR | 104 |
| Prednisone Other prescribers in Corvallis, OR | 80 |
| Abiraterone Acetate | 71 |
| Oxycodone Hcl Other prescribers in Corvallis, OR | 66 |
| Dexamethasone Other prescribers in Corvallis, OR | 59 |
| Prochlorperazine Maleate Other prescribers in Corvallis, OR | 58 |
| Ondansetron Hcl Other prescribers in Corvallis, OR | 57 |
| Anastrozole Other prescribers in Corvallis, OR | 56 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 40 payments worth $1,346 in total to this clinician.
| Tempus Ai, Inc | $262 |
|---|---|
| Janssen Scientific Affairs, LLC | $197 |
| Janssen Biotech, Inc. | $111 |
| AstraZeneca Pharmaceuticals LP | $107 |
| Genentech USA, Inc. | $97.00 |
| Stemline Therapeutics Inc. | $66.81 |
| Merck Sharp & Dohme LLC | $63.41 |
| Dendreon Pharmaceuticals LLC | $53.58 |
| Food and Beverage | $1,273 |
|---|---|
| Education | $73.45 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Dec 5, 2025 | Education in-kind | $53.45 |
| Aveo Pharmaceuticals, Inc. Apr 7, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $37,654 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.